INmune Bio Inc. (INMB)

INmune Bio Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	16.33	24.75	20.92	35.85	52.15	74.81
Cash & Short-Term Investments	16.33	24.75	20.92	35.85	52.15	74.81
Cash Growth	-41.12%	18.30%	-41.64%	-31.26%	-30.29%	240.56%
Other Receivables	1.73	4.54	1.41	2.44	8.46	5.5
Receivables	1.73	4.54	1.41	2.44	8.46	5.5
Prepaid Expenses	0.65	0.6	0.33	1.65	4.06	2.29
Total Current Assets	18.71	29.89	22.66	39.94	64.68	82.61
Property, Plant & Equipment	2.27	1.87	0.31	0.41	0.51	0.73
Other Intangible Assets	-	-	16.51	16.51	16.51	16.51
Other Long-Term Assets	0.53	0.6	0.08	0.13	0.1	0.1
Total Assets	21.51	32.35	39.56	57	81.8	99.95

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	2.23	7.77	6.54	7.9	5.21	3.8
Accrued Expenses	-	0.03	0.03	0.04	0.01	0.01
Current Portion of Long-Term Debt	-	-	-	9.92	5	-
Current Portion of Leases	0.69	0.62	0.14	0.12	0.09	0.07
Other Current Liabilities	-	-	0.52	0.49	0.62	0.47
Total Current Liabilities	2.92	8.42	7.22	18.47	10.92	4.36
Long-Term Debt	-	-	-	-	9.7	14.46
Long-Term Leases	0.52	0.41	0.24	0.4	0.53	0.7
Other Long-Term Liabilities	-	-	-	-	0.55	0.2
Total Liabilities	3.44	8.83	7.47	18.86	21.69	19.72

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.03	0.03	0.02	0.02	0.02	0.02
Additional Paid-In Capital	239.32	233.27	195.75	159.14	151.8	143.92
Retained Earnings	-220.44	-209.04	-163.1	-121.02	-91.01	-63.72
Comprehensive Income & Other	-0.84	-0.74	-0.58	-0.8	-0.7	0
Total Common Equity	18.07	23.52	32.1	37.34	60.1	80.23
Shareholders' Equity	18.07	23.52	32.1	38.14	60.1	80.23
Total Liabilities & Equity	21.51	32.35	39.56	57	81.8	99.95

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1.21	1.03	0.38	10.44	15.31	15.23
Net Cash (Debt)	15.12	23.72	20.54	25.41	36.84	59.58
Net Cash Growth	-43.28%	15.48%	-19.18%	-31.03%	-38.16%	173.20%
Net Cash Per Share	0.56	0.96	1.03	1.41	2.06	3.69
Filing Date Shares Outstanding	30.96	26.59	22.93	17.95	17.95	17.86
Total Common Shares Outstanding	27.92	26.59	22.28	17.95	17.95	17.84
Working Capital	15.79	21.47	15.44	21.48	53.76	78.25
Book Value Per Share	0.65	0.88	1.44	2.08	3.35	4.50
Tangible Book Value	18.07	23.52	15.58	20.83	43.59	63.71
Tangible Book Value Per Share	0.65	0.88	0.70	1.16	2.43	3.57
Machinery	-	1.04	-	-	-	-

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Nov 5, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 8, 2026

Data Sources Report a data error